ESG

A partnership between Biophytis and LynxKite leverages AI to fast-track therapies for sarcopenia and macular degeneration, backed by Singapore's RIE 2030 plan.

As it advances its brain cancer therapies, NeOnc Technologies hires a public company finance expert to steer its next growth phase and ensure fiscal rigor.

As employers grapple with soaring obesity drug costs, a new partnership aims to offer predictable pricing and comprehensive care. Here's how it works.

Aditxt's $36M acquisition of Ignite Proteomics aims to upend cancer therapy by analyzing protein activity, a high-stakes bet for the struggling innovator.

New research reveals a major disconnect: consumers, led by Gen Z, crave sustainable dining, but the foodservice industry is struggling to keep up.

Hancom's OpenDataLoader PDF v2.0 promises top performance, on-premise security, and a roadmap to power the next generation of intelligent AI agents.

A new health tech platform is launching to turn movement into trackable, reimbursable medicine, bridging the gap between doctor's advice and patient action.

A new iPSC-derived cell therapy from Unixell Biotech has gained FDA approval for clinical trials, offering a regenerative approach for millions with epilepsy.

Advocates and doctors urge lowering the colorectal cancer screening age to 45 as rates soar in young adults, sparking a debate on policy and resources.

At SXSW, Reckitt Catalyst and Serena Williams unveil a new cohort of U.S. entrepreneurs tackling America's deep-rooted healthcare access crisis.

The German biotech firm secured its Nasdaq listing, but a near-total investor redemption leaves its cancer-drug pipeline with less than $1M in trust funds.

New EU regulations mandate Digital Product Passports, forcing companies to reveal all. It's a compliance crisis and a circular economy opportunity.

China's BABI launches a 4-in-1 sunscreen using patented tech and Nobel-inspired science to solve irritation, feel, and protection gaps.

The nation's largest beauty retailer is betting big on ingestible wellness, partnering with Cymbiotika to bring advanced supplements to over 1,000 stores.

ROHM's new SiC modules are now on DigiKey, democratizing access to next-gen power tech for EVs and industry, challenging market leaders.

The organic kids' food brand reports impressive sales and a strong IPO, but investors are keenly watching its strategy for long-term profitability.

Data shows Beren Therapeutics' drug slows progression and boosts survival for infantile-onset NPC, a rare disorder with no approved US treatments.

Amid a complex healthcare market, The Ensign Group will outline its aggressive growth and operational playbook for investors at the upcoming Oppenheimer conference.

With a new strategic finance leader, MATEREAL signals a shift from R&D to aggressive commercialization of its 'drop-in' AI-enabled bio-polymers.

A legislative movement across 11 states aims to make scalp cooling, a therapy to prevent hair loss during chemo, an insured part of cancer treatment.